PennyStock101

$PIRS On strong watch for continuation and breakout

Long
NASDAQ:PIRS   Pieris Pharmaceuticals, Inc
Upgrades galore for NASDAQ:PIRS lately as analysts see great upside potential for the company. Most recently PIRS presented data from a phase 1 study on its new technology ANTICALIN which it is developing in collaboration with NYSE:AZN was released and commented on by the Chief development officer. "We are encouraged by the safety and tolerability of AZD1402/PRS-060 in this Phase 1a study, the first Anticalin protein dosed via inhalation,We look forward to completing and presenting the data from the multiple-ascending dose study, which will evaluate the FeNO-reducing potential of this drug candidate versus placebo, at an upcoming medical meeting."
The stock is setting up in a bullish fashion having broken the downtrend resistance, backtested and now moves higher on good volume , while indicators all show significant strength.
AVERAGE ANALYSTS RECOMMENDATION BUY
AVERAGE ANALYSTS TARGET PRICE $7.33


COMPANY PROFILE
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease
areas.

Your Intro To Penny Stock Trading Success...

1) Sign Up for our 100% Free Email Newsletter:
http://www.PennyStock101.org

2) Follow our Telegram Channel @ https://t.me/PennyStock101

3) Join our LIVE CHAT on Discord @ https://discord.gg/qSVhafy
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.